Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Balance Sheet

v3.22.2.2
Condensed Consolidated Interim Balance Sheet - USD ($)
$ in Thousands
Sep. 30, 2022
Jun. 30, 2022
Current assets    
Cash and cash equivalents $ 7,085 $ 11,780
Prepaid expenses, deposits and other 1,071 1,478
Total current assets 8,156 13,258
Clinical trial deposit 4,300 2,600
Property and equipment, net 754 90
Total assets 13,210 15,948
Current liabilities    
Accounts payable and accrued liabilities 2,943 3,269
Related party payables 573 721
Total current liabilities 3,516 3,990
Milestone payment liability 76 163
Total liabilities 3,592 4,153
Stockholders' equity    
Common stock Authorized 275,000 shares at September 30, 2022 (June 30, 2022, $0.001 par value 80,807 issued at September 30, 2022 (June 30, 2022 - 65,533) 81 66
Additional paid-in capital 138,278 135,510
Accumulated deficit (141,316) (136,356)
Accumulated other comprehensive income 21 21
Total stockholders’ equity 9,618 11,795
Total liabilities and stockholders’ equity 13,210 15,948
Preferred Stock Series A    
Stockholders' equity    
Preferred stock 279 279
Preferred Stock Series C    
Stockholders' equity    
Preferred stock $ 12,275 $ 12,275